Floatz logo

PANITUMUMAB

Fragility

Consorci Sanitari del Maresmemonoclonal_antibodyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Fragility cohort.

Asset / SponsorPhaseRating
MIVACURIUM ION
Ankara City Hospital Bilkent
N/AD
RAMIFENTANYL
Ankara City Hospital Bilkent
N/AD
PROPOFOL
Ankara City Hospital Bilkent
N/AD
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Ankara City Hospital Bilkent
N/AD

Same molecule, other indications

PANITUMUMAB is also rated in:

neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →